Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

ClinicalTrials.gov ID: NCT01838499

Public ClinicalTrials.gov record NCT01838499. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

Study identification

NCT ID
NCT01838499
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
AstraZeneca
Industry
Enrollment
224 participants

Conditions and interventions

Interventions

  • MEDI8968 Biological
  • Saline Biological

Biological

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2013
Primary completion
Sep 30, 2014
Completion
Sep 30, 2014
Last update posted
Aug 31, 2016

2013 – 2014

United States locations

U.S. sites
27
U.S. states
14
U.S. cities
27
Facility City State ZIP Site status
Research Site Phoenix Arizona
Research Site Bakersfield California
Research Site Fremont California
Research Site Los Angeles California
Research Site San Diego California
Research Site San Francisco California
Research Site Miami Florida
Research Site Orange Park Florida
Research Site Ormond Beach Florida
Research Site Tampa Florida
Research Site Atlanta Georgia
Research Site Macon Georgia
Research Site Skokie Illinois
Research Site West Dundee Illinois
Research Site Evansville Indiana
Research Site Indianapolis Indiana
Research Site Rockville Maryland
Research Site St Louis Missouri
Research Site Forest Hills New York
Research Site Chapel Hill North Carolina
Research Site High Point North Carolina
Research Site Winston-Salem North Carolina
Research Site Hershey Pennsylvania
Research Site Philadelphia Pennsylvania
Research Site Rapid City South Dakota
Research Site Arlington Texas
Research Site Norfolk Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01838499, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 31, 2016 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01838499 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →